I-TCR
Research type
Research Study
Full title
Immune health for TCR cell therapy manufacturing in non-small cell lung cancer
IRAS ID
259741
Contact name
Sophie Papa
Contact email
Sponsor organisation
King's College London
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
I-TCR is a cohort study of patients with non-small cell lung cancer and healthy volunteers. Cell therapy, made from white blood cells in a persons own immune system and then given back to the patient as a cancer treatment, is an exciting area of clinical research and development at the moment. To ensure we are offering the best chance of activity of the treatment against a cancer we need to make sure the manufacturing of cell therapies is as good as it can be. Part of this involves making sure that different cancer treatments a patient may receive do not have a detrimental impact on the manufacturing or efficiency of a cell product. I-TCR is looking to manufacture TCR gene modified cell therapy in the laboratory from blood cells collected from lung cancer patients at different points in the cancer treatment journey as well as healthy controls, help inform cell therapy manufacturing.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
19/NW/0432
Date of REC Opinion
5 Jul 2019
REC opinion
Further Information Favourable Opinion